A gastrointestinalis stroma tumorok (GIST) kezelésének modern szemlélete

Translated title of the contribution: Modern aspects of the treatment of gastrointestinal stromal tumors (GIST)

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The therapy of choice of resectable GIST is complete surgical removal of the tumor. Lymphadenectomy is not necessary. Following RO resection of the primary tumor long term follow up of the patients is essential. In case of high risk primary (large tumor, high proliferation rate) patients are encouraged to participate in clinical trials administering imatinib mesylate as adjuvant therapy. Patients with irresectable, residual, locally recurrent or metastatic GIST should be treated with 400 mg/day imatinib mesylate (Glivec). In case of primary imatinib resistance patients are advised to participate in clinical trials of new tyrosine kinase inhibitors. In secondary imatinib resistance the daily dose of the drug should be increased up to 800 mg. If further progression occurs one of the new tyrosine kinase inhibitors can be tested in clinical trials. If an originally irresectable GIST can be rendered resectable with "neoadjuvant" imatinib therapy, removal of the tumor should be considered. If resection is not possible imatinib treatment should be continued until progression or toxicity. Efficacy of imatinib terapy can be monitored by CT, MR or pet. Treatment of patients with GIST is multidisciplinary, needing strong cooperation among surgical- and medical oncologists, pathologists and imaging specialists. The complex therapy of GIST patients is ideally performed at specialized oncological centers.

Original languageHungarian
Pages (from-to)935-941
Number of pages7
JournalOrvosi Hetilap
Volume146
Issue number18 SUPPL.1
Publication statusPublished - 2005

Fingerprint

Gastrointestinal Stromal Tumors
Clinical Trials
Therapeutics
Protein-Tyrosine Kinases
Neoplasms
Neoadjuvant Therapy
Imatinib Mesylate
Pets
Lymph Node Excision

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A gastrointestinalis stroma tumorok (GIST) kezelésének modern szemlélete. / Láng, I.; Hitre, E.

In: Orvosi Hetilap, Vol. 146, No. 18 SUPPL.1, 2005, p. 935-941.

Research output: Contribution to journalArticle

@article{80829cba9e494802aacfee199749183a,
title = "A gastrointestinalis stroma tumorok (GIST) kezel{\'e}s{\'e}nek modern szeml{\'e}lete",
abstract = "The therapy of choice of resectable GIST is complete surgical removal of the tumor. Lymphadenectomy is not necessary. Following RO resection of the primary tumor long term follow up of the patients is essential. In case of high risk primary (large tumor, high proliferation rate) patients are encouraged to participate in clinical trials administering imatinib mesylate as adjuvant therapy. Patients with irresectable, residual, locally recurrent or metastatic GIST should be treated with 400 mg/day imatinib mesylate (Glivec). In case of primary imatinib resistance patients are advised to participate in clinical trials of new tyrosine kinase inhibitors. In secondary imatinib resistance the daily dose of the drug should be increased up to 800 mg. If further progression occurs one of the new tyrosine kinase inhibitors can be tested in clinical trials. If an originally irresectable GIST can be rendered resectable with {"}neoadjuvant{"} imatinib therapy, removal of the tumor should be considered. If resection is not possible imatinib treatment should be continued until progression or toxicity. Efficacy of imatinib terapy can be monitored by CT, MR or pet. Treatment of patients with GIST is multidisciplinary, needing strong cooperation among surgical- and medical oncologists, pathologists and imaging specialists. The complex therapy of GIST patients is ideally performed at specialized oncological centers.",
keywords = "GIST, Imatinib mesylate",
author = "I. L{\'a}ng and E. Hitre",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "935--941",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "18 SUPPL.1",

}

TY - JOUR

T1 - A gastrointestinalis stroma tumorok (GIST) kezelésének modern szemlélete

AU - Láng, I.

AU - Hitre, E.

PY - 2005

Y1 - 2005

N2 - The therapy of choice of resectable GIST is complete surgical removal of the tumor. Lymphadenectomy is not necessary. Following RO resection of the primary tumor long term follow up of the patients is essential. In case of high risk primary (large tumor, high proliferation rate) patients are encouraged to participate in clinical trials administering imatinib mesylate as adjuvant therapy. Patients with irresectable, residual, locally recurrent or metastatic GIST should be treated with 400 mg/day imatinib mesylate (Glivec). In case of primary imatinib resistance patients are advised to participate in clinical trials of new tyrosine kinase inhibitors. In secondary imatinib resistance the daily dose of the drug should be increased up to 800 mg. If further progression occurs one of the new tyrosine kinase inhibitors can be tested in clinical trials. If an originally irresectable GIST can be rendered resectable with "neoadjuvant" imatinib therapy, removal of the tumor should be considered. If resection is not possible imatinib treatment should be continued until progression or toxicity. Efficacy of imatinib terapy can be monitored by CT, MR or pet. Treatment of patients with GIST is multidisciplinary, needing strong cooperation among surgical- and medical oncologists, pathologists and imaging specialists. The complex therapy of GIST patients is ideally performed at specialized oncological centers.

AB - The therapy of choice of resectable GIST is complete surgical removal of the tumor. Lymphadenectomy is not necessary. Following RO resection of the primary tumor long term follow up of the patients is essential. In case of high risk primary (large tumor, high proliferation rate) patients are encouraged to participate in clinical trials administering imatinib mesylate as adjuvant therapy. Patients with irresectable, residual, locally recurrent or metastatic GIST should be treated with 400 mg/day imatinib mesylate (Glivec). In case of primary imatinib resistance patients are advised to participate in clinical trials of new tyrosine kinase inhibitors. In secondary imatinib resistance the daily dose of the drug should be increased up to 800 mg. If further progression occurs one of the new tyrosine kinase inhibitors can be tested in clinical trials. If an originally irresectable GIST can be rendered resectable with "neoadjuvant" imatinib therapy, removal of the tumor should be considered. If resection is not possible imatinib treatment should be continued until progression or toxicity. Efficacy of imatinib terapy can be monitored by CT, MR or pet. Treatment of patients with GIST is multidisciplinary, needing strong cooperation among surgical- and medical oncologists, pathologists and imaging specialists. The complex therapy of GIST patients is ideally performed at specialized oncological centers.

KW - GIST

KW - Imatinib mesylate

UR - http://www.scopus.com/inward/record.url?scp=23844495276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844495276&partnerID=8YFLogxK

M3 - Article

C2 - 15921308

AN - SCOPUS:23844495276

VL - 146

SP - 935

EP - 941

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 18 SUPPL.1

ER -